Empagliflozin (Empa) Reduces Heart Failure Outcomes Irrespective of Blood Pressure (Bp), Low Density Lipoprotein Cholesterol (Ldl-C) and Hba1c Control
Canadian Journal of Cardiology - Canada
doi 10.1016/j.cjca.2017.07.336
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2017
Authors
Publisher
Elsevier BV